Lupin Ltd.

Lupin Ltd. is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, India. Founded in 1968 by Desh Bandhu Gupta, it is a publicly traded company listed on the Bombay Stock Exchange (BSE: 500257) and the National Stock Exchange (NSE: LUPIN). As of May 2026, Lupin Ltd. has a market capitalization of approximately $10.76 billion to $10.9 billion USD and employs over 24,000 people globally. The company reported a revenue of approximately $2.81 billion USD for the twelve months ending in 2025. The Gupta family, as the promoter group, retains significant influence with approximately 46.86% of the shares as of March 2026.

Lupin is primarily engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. Its diverse portfolio includes branded and generic formulations, complex generics, biotechnology products (biosimilars), and active pharmaceutical ingredients (APIs). The company's therapeutic focus areas span pediatrics, cardiovascular, anti-infectives, diabetology, asthma, anti-tuberculosis, respiratory, women's health, and central nervous system disorders. Lupin operates globally, with a significant presence in markets such as the United States, Europe, Japan, Australia, and emerging economies.

In terms of patent litigation, Lupin Ltd. appears to operate as a defending company. The provided case data shows one instance where Lupin Ltd. is listed as a defendant and zero as a plaintiff. This indicates that the company is primarily a target of patent infringement allegations rather than an entity actively asserting its own patent portfolio.

The sole tracked case involving Lupin Ltd. is "Otsuka Pharmaceutical Co., Ltd. v. Lupin Ltd. et al.," where Lupin Ltd. is a defendant. This case is being litigated in the U.S. District Court for the District of Delaware.